Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13336996 | 0.91 | CYP3A4 (0.36) | CYP3A4ELANEKCNH2CTSSSTS | |
| SCHEMBL7936511 | 0.90 | CTSS (0.42) | CYP3A4CTSS | |
| SCHEMBL1636582 | 0.90 | CTSS (0.42) | CYP3A4CTSS | |
| SCHEMBL3685793 | 0.90 | CTSS (0.42) | CYP3A4CTSS | |
| SCHEMBL1636580 | 0.90 | CTSS (0.42) | CYP3A4CTSS | |
| SCHEMBL13336904 | 0.90 | CTSS (0.42) | CYP3A4CTSS | |
| SCHEMBL12765130 | 0.88 | CYP3A4 (0.39) | CYP3A4ELANEKCNH2CTSS | |
| SCHEMBL13336771 | 0.85 | CYP3A4 (0.50) | CYP3A4ELANEKCNH2 | |
| SCHEMBL12725995 | 0.85 | CYP3A4 (0.45) | CYP3A4ELANEKCNH2 | |
| SCHEMBL7936165 | 0.84 | CYP3A4 (0.48) | CYP3A4ELANEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CYP3A4 3754/4885ELANE 382/4885KCNH2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.